Keywords: merck, serono, completes, enrollment, pivotal, ph, iii

Merck Serono completes enrollment in pivotal Ph III study of oral cladribine

Article | 22 January 2007

Print This

German drugmaker Merck Serono has completed patient enrollment in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in